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Abstract
Background: Epidemiological studies on risk factors for colorectal cancer (CRC) have mainly
focused on diet, and being overweight is now recognized to contribute significantly to CRC risk.
Overweight and obesity are defined as an excess of adipose tissue mass and are associated with
disorders in lipid metabolism. Peroxisome proliferator-activated receptors (PPARs) and retinoid-
activated receptors (RARs and RXRs) are important modulators of lipid metabolism and cellular
homeostasis. Alterations in expression and activity of these ligand-activated transcription factors
might be involved in obesity-associated diseases, which include CRC. Cyclooxygenase-2 (COX-2)
also plays a critical role in lipid metabolism and alterations in COX-2 expression have already been
associated with unfavourable clinical outcomes in epithelial tumors. The objective of this study is
to examine the hypothesis questioning the relationship between alterations in the expression of
nuclear receptors and COX-2 and the weight status among male subjects with CRC.
Method: The mRNA expression of the different nuclear receptor subtypes and of COX-2 was
measured in 20 resected samples of CRC and paired non-tumor tissues. The association between
expression patterns and weight status defined as a body mass index (BMI) was statistically analyzed.
Results: No changes were observed in PPARγ mRNA expression while the expression of PPARδ,
retinoid-activated receptors and COX-2 were significantly increased in cancer tissues compared to
normal colon mucosa (P ≤ 0.001). The weight status appeared to be an independent factor,
although we detected an increased level of COX-2 expression in the normal mucosa from
overweight patients (BMI ≥ 25) compared to subjects with healthy BMI (P = 0.002).
Conclusion: Our findings show that alterations in the pattern of nuclear receptor expression
observed in CRC do not appear to be correlated with patient weight status. However, the analysis
of COX-2 expression in normal colon mucosa from subjects with a high BMI suggests that COX-
2 deregulation might be driven by excess weight during the colon carcinogenesis process.
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Approximately 5% of individuals will develop colorectal
carcinoma during their lifetime [1]. This disease typically
progresses from adenomatous polyps and dysplastic pol-
yps to invasive carcinoma [2,3]. CRC seems particularly
susceptible to specific nutritional factors and dietary hab-
its (for review [4]). Indeed, excessive consumption of cal-
ories from fat is thought to be largely responsible for the
increasing incidence of CRC in western countries. Moreo-
ver, overweight and obesity status associated with high
body mass indices have been correlated with a higher risk
of developing CRC [5,6]. Nevertheless, the mechanisms of
why and how excess weight increases cancer risk are only
slowly emerging. One proposed mechanism is the rise of
insulin resistance resulting in hyperinsulinemia that can
cause growth-promoting effects [7].
Hyperinsulinemia as well as hyperlipidemia, hyperten-
sion, overweight and type II diabetes are metabolic disor-
ders which might be caused by alterations in the
homeostasis of the metabolism of fatty acids [8]. These
obesity-related symptoms could affect the integrity of
colon tissue homeostasis and therefore be involved in
CRC etiology [9]. Anti-diabetic treatments initially used
for improving parameters such as insulin sensitivity have
been shown to be able to inhibit colon carcinogenesis in
rodent models [10,11] and to promote differentiation of
colon cancer cells [12]. Moreover, concomitant suppres-
sion of hyperlipidemia and polyp formation were
observed in APC-deficient mice treated with insulin-sensi-
tizing drugs called thiazolidinediones (TZD) [13]. In such
a context, PPAR family members initially recognized for
their involvement in regulating fat metabolism and adi-
pogenesis have emerged as attractive targets for therapeu-
tic approaches for obesity and CRC. Indeed, PPARγ
agonists including anti-diabetic agents, polyunsaturated
fatty acids as well as non-steroidal anti-inflammatory
drugs (NSAID) [14,15] have been demonstrated to affect
proliferation and differentiation in cancer cell lines [16].
Moreover, both anti-proliferative effects of PPARγ
observed in vitro [12] and inactivating mutations in the
PPARγ gene found in colon tumors [17] provide evidence
for a tumor suppressor function. This is also supported by
the finding that an increased risk of polyp occurrence in
colon mucosa was found to be significantly associated
with a decrease in PPARγ mRNA expression [18]. Another
isotype, PPARδ, may also play an important role in the
process of colon carcinogenesis since it has been effi-
ciently targeted by hypolipidemic and hypoglycemic
drugs [19]. However, PPARδ might display distinct func-
tions in lipid metabolism and colon carcinogenesis.
Indeed and in contrast to PPARγ, PPARδ was found fre-
quently overexpressed in colon cancer cells [20] and
tumors of chemically-initiated animals [21]. Nevertheless,
the role of PPARδ in colonic epithelium stays unclear due
to conflicting evidence [22].
The transcriptional activity of PPAR depends on the pres-
ence of the retinoic X receptor (RXR), activated by 9-cis
retinoic acid (9-cis RA). Heterodimerization with RXR is
essential for the activity of all class II nuclear receptors
[23] and explains how fatty acids and retinoids control
lipid metabolism [24]. The active forms of vitamin A, 9-cis
RA and all-trans retinoic acid (atRA), also exhibit anti-
tumoral properties in many tissues mainly through RXR
and retinoic acid-activated receptor (RAR) binding.
Indeed, retinoids have displayed chemopreventive and
chemotherapeutic activities with regard to their capacity
to induce cell differentiation and apoptosis (for review
[25]). RXRα is by far the most prevalent isoform in the
colon, while RXRβ and RXRγ are expressed at low levels
[26]. All three RAR isotypes, α, β, and γ, are expressed and
induced by retinoids in colon cancer cell lines [27]. Alter-
ations in retinoid-activated receptor expression and bio-
logical activity have been observed both in vivo and in vitro
[28]. However, potential alterations have been poorly
investigated in CRC although they may affect the response
of target cells to retinoid and lipid derivatives.
COX-2 is a key enzyme in lipid metabolism and is well-
known to convert arachidonic acid to growth-regulating
molecules such as prostaglandins. COX-2, activated by
growth factors and pro-inflammatory cytokines, has been
shown to be overexpressed in several epithelial cancers
including CRC [29,30]. This enzyme might mediate the
promotion of colon carcinogenesis by metabolic disor-
ders and inflammation and several lines of evidence indi-
cate that COX-2 might be regulated by PPARγ [31] and
RARβ activation in cancer cells [32,33] although the
mechanism is unclear. It was also shown that deregula-
tions in nuclear receptor expression might promote COX-
2 upregulation [34].
In the current report, our interest was (i) to evaluate alter-
ations in the expression of the different nuclear receptors
and COX-2 in several colon cancer specimens from
patients undergoing surgery to remove tumors and (ii) to
clarify whether or not the expression of nuclear receptors




Tumor samples and normal adjacent tissue microscopi-
cally confirmed to be free of cancer were obtained from 20
patients undergoing surgery for colorectal cancer at the St.
André Hospital (Bordeaux, France) from January 2003 to
September 2004. Following surgery, samples from tumor
and adjacent normal mucosa were frozen in liquid nitro-Page 2 of 10
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All included patients were men without neoadjuvant
treatment. Patients suffering from familial cancer syn-
dromes were excluded. Information concerning age, BMI
(weight (kg)/height (m)2), tumor site, pTNM and Dukes
stage are indicated in Table 1. BMI was found not to be
correlated with height in this population (r = 0.07, n =
20), but strongly correlated with weight (r = 0.89, n = 20).
Segregation of patients into BMI groups corresponded to
the following categorizations: 18.5–25 kg/m2 (healthy
weight), ≥ 25 kg/m2 (excess weight group including over-
weight/pre-obese/obese subjects).
RNA extraction and reverse transcription (RT)
Total RNA was extracted from colon tissue samples using
the RNAgents Total RNA Isolation System kit according to
the manufacturer's instructions (Promega, Charbon-
nières, France). Reverse transcription was as follows: 2 µg
of total RNA was mixed with RNasin (1 U/µL, Promega,
Charbonnières, France) and DNase I (0.5 U/µL, Roche
Diagnostics, Meylan, France) and incubated 15 min at
37°C. Reverse primers (0.75 µM of each) were added and
incubated for 10 min at 70°C. ImProm-II™ 5× reaction
buffer (1×, Promega, Charbonnières, France), MgCl2 (2.5
mM, Promega, Charbonnières, France), dNTP (0.5 mM
each one, Roche Diagnostics, Meylan, France) and
ImProm-II™ Reverse Transcriptase (Promega, Charbon-
nières, France) were added for 1 hr at 42°C. The total vol-
ume was 20 µL and each target mRNA was co-reverse
transcribed with β2-microglobulin mRNA.
Real-time Polymerase Chain Reaction (PCR)
Real-time quantitative PCR involving LightCycler™ tech-
nology (Roche Diagnostics, Mannheim, Germany), was
performed according to the protocol recommended by the
manufacturer and previously described [34]. SYBR green I
fluorescence dye was sufficiently sensitive to accurately
detect amplified products from all target cDNA (PPARδ,
PPARγ, RARα, RXRα and COX-2) except for RARβ and
RARγ amplified product detected using dual-labeled and
specific TaqMan fluorogenic probes. Quantification data
were analyzed using the LightCycler Relative Quantifica-
tion Software (Roche Diagnostics, Mannheim, Germany).
The software provides a crossing point (Cp), defined as
the PCR cycle number, function of the log of the DNA
concentration (in ng). A standard curve is a plot of the Cp
versus the amount of initial cDNA used for amplification.
Standard curves were used to estimate the concentration
of both the target and the reference gene in each sample.
This software provides a calibrator-normalized relative
quantification including PCR efficiency correction consid-
ering then the difference existing between amplification
efficiencies of reference and target cDNAs. cDNA from tis-
sue samples from patient A was arbitrarily chosen to be
the calibrator. The cDNA calibrator was used in all exper-
iments. Results are expressed as the target:reference ratio
divided by the target:reference ratio of the calibrator.
Primers and fluorogenic probes were purchased from Pro-
ligo France (Paris, France). Each probe was synthesized
with the fluorescent reporter dye FAM (6-carboxy-fluores-
cein) attached to the 5'-end and a quencher dye TAMRA
Table 1: Summary of clinical and pathological data
Case n° Age BMI Ta Na Ma Dukesb Site
1 80 20.83 4 1 x C asc. colon
2 80 29.75 3 1 x C asc. colon
3 72 38.75 3 1 x C rectum
4 82 31.41 3 0 x B rectum
5 81 21.47 3 0 x B sigmoid
6 69 25.34 3 0 x B asc. colon
7 56 24.68 3 1 1 D asc. colon
8 66 21.91 3 0 x B asc. colon
9 69 24.34 4 1 x C rectum
10 86 24.91 4 1 1 D asc. colon
11 87 23.03 3 1 x C rectum
12 66 27.68 4 0 x B sigmoid
13 73 28.13 4 1 x C sigmoid
14 71 34.60 3 1 x C rectum
15 60 30.24 2 0 1 D sigmoid
16 61 26.12 3 0 x B sigmoid
17 41 18.73 4 1 x C asc. colon
18 85 25.95 3 1 x C asc. colon
19 72 29.06 2 0 1 D des.colon
20 76 22.72 3 1 1 D rectum
a According to the TNM classification : T, primary tumor; N, regional lymph nodes; M, metastasisb According to the Dukes classification
b According to the Dukes classificationPage 3 of 10
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icity of primers was validated through the verification of
RT-PCR product specificity. RT-PCR products were sub-
jected to analysis by electrophoresis on a 1.5% agarose gel
and resulted in a single product with the desired length
(β2-microglobulin, 112 bp; PPARδ, 139 bp; PPARγ, 144
bp; RARα, 235 bp; RARβ, 133 bp; RARγ, 167 bp; RXRα,
142 bp; COX-2, 130 bp). The identity of amplified prod-
ucts were assessed by sequencing with a Dye Terminator
Reaction Cycle Kit (Perkin-Elmer, Norwalk, CT) and were
analyzed on an ABI PRISM™ 377 automated DNA
sequencer (Perkin-Elmer). The forward and reverse primer
sequences and the probes were as follows:
β2-microglobulin: sense 5' CTTGGGCTGTGACAAAGTC 3',
antisense 5' GTCTTTC-AGCAAGGACTGG 3', Taqman
probe 5' (6-Fam)TGGTTCACTCGGCAGGCATAC-
TC(Tamra) 3';
PPARδ: sense 5'GGGAGAGGTCTGTGTAGCTGCTG 3',
antisense 5' ATGGAGCA-GCCACAGGAGGAAGCC 3';
PPARγ: sense 5' CGGATGGCCACCTCTTTGCTC 3', anti-
sense 5' GGCGAGGGCG-ATCTTGACAGG 3';
RARα: sense 5' ACGTTGTTCTGAGCTGTTGTTCGTA 3',
antisense 5' CTGCCAGT-ACTGCCGACTGC 3';
RARβ: sense 5' AG-GCTTGCTGGGTCGTCTTT 3', anti-
sense 5' CCTTCTCAGTGC-CATCTGCTTAAT 3', Taqman
probe 5' (6-Fam)AGACCGCCAGGACCTTGAGGA-
ACCGA(Tamra) 3';
RARγ: sense 5' GCAAAGACAAGGTCTGT-GAG 3', anti-
sense 5' GACCAGATCAC-TCTGCTCAAAGC 3', Taqman
probe 5' (6-Fam)TATCCTGATGCTGCGTATCTGC-
ACAAGGT(Tamra);
RXRα: sense 5' GAGCAGCTTATTCCAGCCTGCC 3', anti-
sense 5' CGACCCTGTC-ACCAACATTTGC 3';
COX-2: sense 5'TGGTGCCTGGTCTGATGAT 3', antisense
5' GCCTGCTTGTCTG-GAACAAC 3'
Statistical methods
Statistical analyses were carried out using the Windows
SPSS® 9.0 software package. Associations between clinico-
pathological variables (age, TNM and Dukes stage (Dukes
B vs. C vs. D), BMI (BMI < 25 vs. BMI ≥ 25), tumor site
(descendant/sigmoid colon/rectum vs. ascendant colon))
were assessed by Spearman's correlation coefficient test.
Associations between mRNA expression levels were tested
for correlation by Spearman's test and mRNA levels were
compared with regard to clinicopathological features.
Specifically, comparison of mRNA expression levels in
healthy tissue with regard to BMI and tumor site was per-
formed using the Mann-Whitney U test. The Kruskal-Wal-
lis test was used to assess for significant differences in
mRNA expression with regard to Dukes stage (Dukes B vs.
C vs. D). The significance of differences in mRNA expres-
sion levels between healthy mucosa and tumor tissue was
evaluated using the Wilcoxon-test. A P value < 0.05 was
considered as significant.
Results
Samples of CRC specimens and adjacent non-neoplastic
colonic mucosa were collected from patients undergoing
surgery. Pertinent clinical and pathological data are listed
in Table 1. All patients were men with a median age of 72
years old (range 41–87). Six patients (30%) had Dukes' B
tumors, nine patients (45%) were classified as Dukes' C or
as Dukes' D (25%). Eleven patients (55%) had a BMI
greater than 25, and were designated as overweight. Four
of these had a BMI value above 30, corresponding to obes-
ity status. No correlation was found between age, BMI,
and tumor classification.
Table 2: Nuclear receptor and COX-2 mRNA expression in colorectal tumors
Gene n Normal colon mucosa Tumor tissue pa
Median Range Median Range
PPARγ 20 0.96 (0.35–3.19) 1.04 (0.28–4.71) n.s.
PPARδ 20 1.30 (0.69–2.34) 1.54 (0.40–4.96) 0.001
RXRα 20 0.75 (0.20–1.25) 0.95 (0.21–3.49) <0.001
RARα 20 1.13 (0.69–1.88) 1.44 (0.38–3.93) <0.001
RARβ 20 1.42 (0.12–5.39) 2.20 (0.18–10.82) <0.001
RARγ 20 1.37 (0.49–9.52) 3.42 (0.83–15.80) <0.001
COX-2 20 1.50 (0.44–6.75) 12.80 (0.50–560.5) <0.001
Statistical analyses were performed using Wilcoxon-test
n.s. not significant
a Wilcoxon testPage 4 of 10
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tive real-time RT-PCR in all normal-looking tissue and
tumor samples. The median mRNA expression values are
shown in Table 2. The median relative PPARγ expression
level in tumors remained unchanged as compared to nor-
mal mucosa. Indeed, among 20 investigated cancer tissue
samples, PPARγ increased between 1.5- and 4-fold in 35%
(n = 7), while we noted a 1.5- to 6-fold decrease in 25%
(n = 5). No changes were observed in the remaining 40%
(n = 8). In contrast, the expression of PPARδ in tumors
was significantly upregulated (1.54 vs. 1.30, P = 0.001)
relative to normal mucosa. All retinoid nuclear receptors
were also upregulated in tumor tissues compared to
healthy mucosa (n = 20, P < 0.001). Expression levels
were increased by the following percentages: RXRα
26.7%, RARα 27.4%, RARβ 54.9%, and RARγ 149.6%.
COX-2 mRNA expression was multiplied by 8.5 between
normal and tumor tissues (P < 0.001). Relationships
between nuclear receptor and COX-2 mRNA expression
were tested statistically and listed in Tables 3 and 4 (see
also additional file 1). Further combined analysis of
receptor and COX-2 mRNA expression levels with regard
to Dukes' stages and tumor localisations did not display
any significant statistical difference. COX-2 expression
was not correlated with tumor stages and localisations
(data not shown), but was associated with RARα and
RARβ mRNA expression in tumor tissue (Table 4).
Differences in expression of nuclear receptors and COX-2
between normal and tumor tissues (Table 2) were also
observed when patients were segregated into groups with
low and high BMI (BMI < 25 vs. BMI ≥ 25) (Tables 5 and
6). We also compared the expression of nuclear receptors
and COX-2 in healthy mucosa regarding the BMI of
patients (Table 7). Statistics revealed that COX-2 expres-
sion is significantly increased in the normal-looking
mucosa from patients with the highest BMI (Table 7).
Discussion
Nuclear receptors are involved in many cellular processes
from embryonic development to cell death. Dysfunction
of nuclear receptor signaling can lead to proliferative and
metabolic diseases such as cancer and obesity. In the cur-
rent report, we assessed the mRNA expression levels of
nuclear receptors and COX-2 in 20 CRC specimens and
sought a possible relationship with patient's weight status
defined by BMI ranging from 18.7 to 38.7.
PPARγ constitutes the most extensively studied of the
three PPAR subtypes (α, β, γ) since its function relates to
lipid metabolism as well as cell differentiation, apoptosis
and cancer. PPARγ can be activated by certain lipids and
derivatives and by anti-diabetic agents. Activated PPARγ
has been shown able to stimulate differentiation and
apoptosis in cancer cells from various origins [35-38].
Nevertheless, in contrast with results generated in vitro,
data concerning PPARγ expression in human cancer spec-
Table 4: Associations between nuclear receptor and COX-2 expression in colorectal tumors
PPARγ PPARδ RXRα RARα RARβ RARγ COX-2




0.408 (0.001) 0.105 (n.s.) 0.436 (<0.001) -0.191 (n.s.)
PPARδ 1.000 0.620 
(<0.001)
0.773 (<0.001) 0.571 (<0.001) 0.601 (<0.001) 0.407 (n.s.)
RXRα 1.000 0.577 (<0.001) 0.438 (<0.001) 0.425 (0.001) 0.161 (n.s.)
RARα 1.000 0.581 (<0.001) 0.538 (<0.001) 0.291 (0.024)
RARβ 1.000 0.434 (0.001) 0.453 (<0.001)
RARγ 1.000 0.202 (n.s.)
COX-2 1.000
n.s. not significant
a correlation coefficient with the p value from Spearman's test in parentheses
Table 3: Associations between nuclear receptor and COX-2 expression in healthy colorectal mucosa
PPARγ PPARδ RXRα RARα RARβ RARγ COX-2
PPARγ 1.000 0.104 (n.s.) 0.324 (0.012)a 0.107 (n.s.) 0.330 (0.010) -0.017 (n.s.) 0.170 (n.s.)
PPARδ 1.000 0.179 (n.s.) 0.277 (0.032) -0.001 (n.s.) -0.119 (n.s.) -0.145 (n.s.)
RXRα 1.000 0.255 (0.049) 0.233 (n.s.) 0.111 (n.s.) 0.003 (n.s.)
RARα 1.000 0.2580 (0.046) -0.112 (n.s.) 0.134 (n.s.)
RARβ 1.000 -0.294 (0.023) 0.173 (n.s.)
RARγ 1.000 0.261 (0.044)
COX-2 1.000Page 5 of 10
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of the receptor in vivo. For example, PPARγ was found
highly expressed in ovarian carcinoma [39] and its overex-
pression in pancreatic carcinoma was associated with
poor prognosis [40]. By contrast, our data, in agreement
with others [41], showed PPARγ expression globally
unchanged in CRC compared with adjacent normal tis-
sues, although Dubois et al. [42] found a marked increase
of PPAR mRNA expression in four CRC samples and in
different colon cancer cell lines. Discrepancies might be
attributed to germline mutations in the adenomatous
polyposis gene (APC). Indeed, PPARγ has been involved
in increasing resistance towards carcinogens by prevent-
ing the accumulation of β-catenin, which is regulated by
APC. However, PPARγ functions are lost when APC is
mutated [43]. Another report has shown that deregulated
APC/β-catenin indirectly induced aberrant PPARγ overex-
pression [44], explaining previous experimental data in
APCMin/+ mice showing a promoting effect of PPARγ on
carcinogenesis [45]. This has relevance for humans
because mutations in the tumor suppressor gene APC are
the initiating event in about 85% of sporadic CRC. There-
fore, APC status could dramatically affect expression and
function of PPARγ and the steady-state levels of PPARγ
reported here do not exclude loss of PPARγ transcriptional
activity due to somatic mutations [17], alterations in
intracellular distribution [46], post-translation modifica-
tions [47] or inhibition by PPARδ [48].
Like PPARγ, PPARδ gene expression is detected in the
colon and the receptor can be activated by fatty acids and
derivatives. Herein, we reported an elevated level of
PPARδ (~18%) in CRC. Upregulation of PPARδ gene
expression might be attributed to deregulation in the
APC/β-catenin pathway since PPARδ is considered to be a
downstream target gene [20]. Increased levels of PPARδ
expression have already been observed in rodent colorec-
tal tumors and in primary human colorectal adenocarci-
nomas [20,21]. Nevertheless, PPARδ function remains
elusive, with data showing that PPARδ was dispensable
for polyp formation [49]. Our data and others suggested a
contribution of PPARδ in the carcinogenesis process
[16,50] while Marin et al. [22] described that agonist-acti-
vated PPARδ protects against cancer development. As for
PPARγ, the integrity of the tumor suppressor APC might
be essential to guarantee PPARδ normal function.
Critical to the transcriptional activity of PPARs is the abil-
ity to form a complex with RXR and bind to DNA. Syn-
thetic ligands of RXRα were shown to exhibit insulin-
sensitizing activity [51,52] and to act synergistically with
PPARγ ligands to enhance PPARγ/RXRα-mediated transac-
tivation [31]. In addition, a positive correlation in healthy
mucosa was found between RXRα and PPARγ supporting
the idea of a tight relationship in the regulation of the
expression of these receptors. While no change in RXRα
expression level was previously noted in 17 patients with
CRC [41], our data revealed a significant increase in tumor
Table 6: Nuclear receptor and COX-2 mRNA expression in colorectal tumors of patients with BMI ≥ 25
Gene n Healthy colon mucosa Tumor tissue pa
Median Range Median Range
PPARγ 11 0.95 (0.35–2.11) 0.97 (0.28–4.71) n.s.
PPARδ 11 1.28 (0.72–2.00) 1.52 (0.40–4.49) 0.022
RXRα 11 0.64 (0.20–1.25) 0.85 (0.21–3.49) 0.047
RARα 11 1.17 (0.72–1.88) 1.44 (0.38–3.72) 0.018
RARβ 11 1.30 (0.12–5.39) 2.12 (0.24–10.82) 0.014
RARγ 11 1.60 (0.49–9.52) 3.17 (0.83–15.80) <0.001
COX-2 11 2.93 (0.44–6.75) 13.20 (0.85–166.86) <0.001
Table 5: Nuclear receptor and COX-2 mRNA expression in colorectal tumors of patients with BMI < 25
Gene n Healthy colon mucosa Tumor tissue pa
Median Range Median Range
PPARγ 9 1.00 (0.65–3.19) 1.17 (0.35–3.67) n.s.
PPARδ 9 1.35 (0.69–2.34) 1.55 (0.57–4.96) 0.012
RXRα 9 0.76 (0.37–1.20) 1.09 (0.54–1.84) <0.001
RARα 9 1.09 (0.69–1.85) 1.58 (0.95–3.93) <0.001
RARβ 9 1.53 (0.52–2.49) 2.78 (0.18–8.49) 0.001
RARγ 9 1.21 (0.76–3.68) 4.49 (0.91–9.68) <0.001
COX-2 9 1.11 (0.51–3.48) 12.40 (0.50–560.46) <0.001Page 6 of 10
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observed in human esophageal [53], breast [54] and
hepatocellular carcinomas [32]. However, little is known
about the function of RXRα in colon tumorigenesis and
our results do not rule out the possibility of alterations in
RXRα functions due to altered localization [55] or inhibi-
tory effect of unliganded RXRα on PPARγ transactivation
[56].
Recent data have also suggested that PPARγ anti-tumor
activity required a functional RARβ [57]. This implies that
PPARγ function may be affected by alterations in the retin-
oid pathway. To our knowledge, very few reports have
examined the expression of retinoid receptors in CRC.
Therefore, we described here the first detailed analysis of
nuclear receptor RARα, β and γ mRNA expression in CRC.
RARβ has been extensively studied in cancer cells and
human carcinomas, and several studies have suggested
that it may play a role as a tumor suppressor gene [58-60].
However, our results showed a significant upregulation in
the expression of all three RAR isotypes in CRC specimens
compared to adjacent normal mucosa. Furthermore, we
showed a complex association between the expression of
mRNA for RXRα, RARs, and PPARs in cancer tissue, sug-
gesting interactions and cross-talk between these receptors
in tumorigenesis. These results demonstrated that altera-
tions are not restricted to a single receptor. Instead, we
observed a profound dysregulation of the retinoid path-
way in this CRC. Downregulation of mRNA expression of
RARβ often observed in cancer cells has been considered
as a cellular mechanism to prevent retinoid-induced
growth arrest [61,62]. On the other hand, while elevated
levels of RAR mRNA expression has also been described in
breast, liver and esophageal tumors [53,63,64], mecha-
nism and significance are unknown. Nevertheless, if the
expression of RAR correlates with tissue sensitivity to
retinoids, our results should be confirmed within a larger
number of samples and both the mechanism leading to
inappropriate RXR and RAR expression and the response
of CRC to retinoids should be investigated.
There are strong correlations between the intake of fatty
acids, the establishment of metabolic disorders and an
increased risk of developing CRC [65,66]. This suggests
the involvement of PPARs and retinoid receptors, acti-
vated by fatty acids and derivatives [21] and modulated by
metabolic disorders [67] in establishing a link between
overweight prevalence and CRC pathogenesis. In the cur-
rent report, we aimed to clarify whether aberrations in the
expression of nuclear receptors may contribute to associ-
ate high BMI and CRC. However, alterations in nuclear
receptor expression observed in tumors were similar in
both patients with low or high BMI. We also investigated
COX-2 expression which is involved in cellular responses
to lipids and inflammatory processes that favour tumori-
genesis by stimulating cell proliferation and angiogenesis
[68]. Interestingly, while COX-2 was greatly expressed in
CRC as previously shown [69], we also found a signifi-
cantly increased level of COX-2 expression in normal
mucosa from patients with high BMI compared to low
BMI patients. Recently, it has been reported that patients
with a high risk of developing CRC presented an upregu-
lation of the COX-2 gene in normal-looking colon
mucosa [70]. This supports the idea that COX-2 deregula-
tion might be an early event in the process of carcinogen-
esis. Nevertheless, although previous reports showed
COX-2 regulation by nuclear receptors [31,71], very few
associations were found in our study between COX-2 and
nuclear receptor expression. In conclusion, our study
described altered expression of nuclear receptors in CRC
specimens. Further studies are warranted in order to deter-
mine the underlying mechanism leading to altered expres-
sion of PPARs and retinoid-activated receptors and the
significance of such alterations. Moreover, alterations in
nuclear receptor expression were independent of the
weight status of patients. Nevertheless, COX-2 might be
Table 7: Comparison between nuclear receptor and COX-2 mRNA expression in healthy colorectal mucosa from patients with BMI < 
25 or with BMI ≥ 25
Gene BMI < 25 BMI ≥ 25 pa
n Median Range n Median Range
PPARγ 9 1.00 (10.65–3.19) 11 0.95 (0.35–2.11) n.s.(0.882)
PPARδ 9 1.35 (0.69–2.34) 11 1.28 (0.72–2.00) n.s.(0.882)
RXRα 9 0.76 (0.37–1.20) 11 0.64 (0.20–1.25) n.s.(0.095)
RARα 9 1.09 (0.69–1.85) 11 1.17 (0.72–1.88) n.s.(0.824)
RARβ 9 1.53 (0.52–2.49) 11 1.30 (0.12–5.39) n.s.(0.370)
RARγ 9 1.21 (0.76–3.68) 11 1.60 (0.49–9.52) n.s.(0.230)
COX-2 9 1.11 (0.51–3.48) 11 2.93 (0.44–6.75) 0.002
Statistical analyses were performed using Mann-Whitney test
n.s. not significant
a Mann-Whitney testPage 7 of 10
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ated metabolic disorders and consequently might affect
nuclear receptor expression and activation.
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